Matches in SemOpenAlex for { <https://semopenalex.org/work/W68505867> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W68505867 endingPage "34" @default.
- W68505867 startingPage "1526" @default.
- W68505867 abstract "The general pharmacological properties of 1-cyclohexyl-4-[ethyl(p-methoxy-alpha-methylphenethyl)amino]-1-butanone hydrochloride (secoverine hydrochloride), a neurotropic spasmolytic agent with specific antimuscarinic properties, are described. 1. No effects on blood pressure were seen in dogs with doses up to 3 mg/kg .i.v. In hypertensive rats no blood pressure lowering effect was seen after oral doses of 25 and 100 mg/kg. In cats a marginal increase of the blood pressure was observed with i.v. doses up to 3 mg/kg, in pentobarbital-anaesthetized animals. This effect was not present in the chloralose-anaesthetized animal. The sinus carotis occlusion pressor reflex was increased at doses of 0.1 and 0.3 mg/kg but was decreased after an i.v. dose of 3 mg/kg. At a dose of 1 mg/kg i.v. a small decrease in heart contractility was seen. At relative high concentrations, secoverine showed in vitro a non-specific negative inotropic effect on the isolated atrium and rat ventricle strip. 2. No serious effects on the ECG were found in dogs with i.v. doses up to 10 mg/kg. In rabbits at 1 mg/kg i.v. atrioventricular dissociation was seen. In cats irregularly, anaesthetic dependent ventricular ectopics were observed. 3. With 10 mg/kg i.v. doses in rabbits some increase in respiration volume occurred, due to an increase in respiratory frequency and tidal volume. 4. Secoverine had no central depressant effects. In high doses central stimulating effects probably related to the antimuscarinic activity were found. 5. Secoverine did not cause ulceration of the stomach wall of the rat during acute or prolonged oral administration of high doses. A potentiation of ulceration was observed in Shay rats; however, the ulceration in rats caused by acetyl salicylic acid and by reserpine was antagonized by the compound. 6. No effects were seen on blood glucose levels, blood coagulation, platelet aggregation, detoxification mechanisms and diuresis, neither were analgetic or antiinflammatory effects observed." @default.
- W68505867 created "2016-06-24" @default.
- W68505867 creator A5010680683 @default.
- W68505867 creator A5046752511 @default.
- W68505867 date "1980-01-01" @default.
- W68505867 modified "2023-10-14" @default.
- W68505867 title "Pharmacology of secoverine, a new spasmolytic agent with specific antimuscarinic properties. Part 2: General pharmacological properties." @default.
- W68505867 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7193021" @default.
- W68505867 hasPublicationYear "1980" @default.
- W68505867 type Work @default.
- W68505867 sameAs 68505867 @default.
- W68505867 citedByCount "3" @default.
- W68505867 crossrefType "journal-article" @default.
- W68505867 hasAuthorship W68505867A5010680683 @default.
- W68505867 hasAuthorship W68505867A5046752511 @default.
- W68505867 hasConcept C126322002 @default.
- W68505867 hasConcept C158328960 @default.
- W68505867 hasConcept C170493617 @default.
- W68505867 hasConcept C2776725644 @default.
- W68505867 hasConcept C2776755955 @default.
- W68505867 hasConcept C2776885963 @default.
- W68505867 hasConcept C2776894844 @default.
- W68505867 hasConcept C2777953023 @default.
- W68505867 hasConcept C2778750930 @default.
- W68505867 hasConcept C2779904517 @default.
- W68505867 hasConcept C2780660124 @default.
- W68505867 hasConcept C2780795376 @default.
- W68505867 hasConcept C2908806481 @default.
- W68505867 hasConcept C2909081213 @default.
- W68505867 hasConcept C33789571 @default.
- W68505867 hasConcept C39133596 @default.
- W68505867 hasConcept C42219234 @default.
- W68505867 hasConcept C71924100 @default.
- W68505867 hasConcept C83974742 @default.
- W68505867 hasConcept C84393581 @default.
- W68505867 hasConcept C98274493 @default.
- W68505867 hasConceptScore W68505867C126322002 @default.
- W68505867 hasConceptScore W68505867C158328960 @default.
- W68505867 hasConceptScore W68505867C170493617 @default.
- W68505867 hasConceptScore W68505867C2776725644 @default.
- W68505867 hasConceptScore W68505867C2776755955 @default.
- W68505867 hasConceptScore W68505867C2776885963 @default.
- W68505867 hasConceptScore W68505867C2776894844 @default.
- W68505867 hasConceptScore W68505867C2777953023 @default.
- W68505867 hasConceptScore W68505867C2778750930 @default.
- W68505867 hasConceptScore W68505867C2779904517 @default.
- W68505867 hasConceptScore W68505867C2780660124 @default.
- W68505867 hasConceptScore W68505867C2780795376 @default.
- W68505867 hasConceptScore W68505867C2908806481 @default.
- W68505867 hasConceptScore W68505867C2909081213 @default.
- W68505867 hasConceptScore W68505867C33789571 @default.
- W68505867 hasConceptScore W68505867C39133596 @default.
- W68505867 hasConceptScore W68505867C42219234 @default.
- W68505867 hasConceptScore W68505867C71924100 @default.
- W68505867 hasConceptScore W68505867C83974742 @default.
- W68505867 hasConceptScore W68505867C84393581 @default.
- W68505867 hasConceptScore W68505867C98274493 @default.
- W68505867 hasIssue "9" @default.
- W68505867 hasLocation W685058671 @default.
- W68505867 hasOpenAccess W68505867 @default.
- W68505867 hasPrimaryLocation W685058671 @default.
- W68505867 hasRelatedWork W1609734160 @default.
- W68505867 hasRelatedWork W1985136220 @default.
- W68505867 hasRelatedWork W1999697897 @default.
- W68505867 hasRelatedWork W2008130743 @default.
- W68505867 hasRelatedWork W2033113013 @default.
- W68505867 hasRelatedWork W2053781081 @default.
- W68505867 hasRelatedWork W2278984028 @default.
- W68505867 hasRelatedWork W2419559830 @default.
- W68505867 hasRelatedWork W2428623185 @default.
- W68505867 hasRelatedWork W68505867 @default.
- W68505867 hasVolume "30" @default.
- W68505867 isParatext "false" @default.
- W68505867 isRetracted "false" @default.
- W68505867 magId "68505867" @default.
- W68505867 workType "article" @default.